Purchase this article with an account.
Roger A Goldberg, Jeffrey S. Heier; Short-Term Oral Mifepristone for the Treatment of Central Serous Chorioretinopathy (STOMP CSC) – A Randomized, Placebo-Controlled Study. Invest. Ophthalmol. Vis. Sci. 2018;59(9):782.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To investigate the efficacy and safety of mifepristone, a GR2-receptor antagonist, for patients with chronic and/or recurrent central serous chorioretinopathy.
Randomized, double-masked, multi-site, placebo-controlled trial of mifepristone 300- and 900-mg daily for four weeks. Central retinal thickness (CRT) and visual acuity (BCVA) were measured throughout the study.
30 patients were randomized to placebo, 300- or 900 mg. Patients assigned to active treatment had a significant reduction in CRT (82 microns; p<0.05) and improvement in BCVA (3.6 ETDRS letters; p<0.05). Patients assigned to placebo did not have a significant change in CRT (47 microns) or BCVA (0.7 letters). Comparison of change in CRT between active- and placebo-treated patients did not reach statistical significance (p=0.15). Mifepristone was well tolerated.
Oral mifepristone may reduce subretinal fluid and improve visual acuity in patients with CSC. Larger studies are warranted to extend these findings.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only